Which has higher earnings and valuation, CLYM or OKUR?

Climb Bio is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Climb Bio N/A N/A -$59.85M -$0.78 N/A OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A

Is CLYM or OKUR more profitable?

Climb Bio's return on equity of -31.45% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% OnKure Therapeutics N/A -61.02% -55.99%

Does the media favor CLYM or OKUR?

In the previous week, Climb Bio had 9 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Climb Bio and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Climb Bio's score of 0.43 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRMD or OKUR?

In the previous week, CorMedix had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for CorMedix and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat CorMedix's score of 0.57 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, DSGN or OKUR?

Design Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A

Is DSGN or OKUR more profitable?

Design Therapeutics' return on equity of -33.07% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% OnKure Therapeutics N/A -61.02% -55.99%

Does the media prefer DSGN or OKUR?

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Design Therapeutics' average media sentiment score of 0.94 equaled OnKure Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TLRY or OKUR?

In the previous week, Tilray Brands had 20 more articles in the media than OnKure Therapeutics. MarketBeat recorded 22 mentions for Tilray Brands and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Tilray Brands' score of 0.51 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 3 Very Positive mention(s) 7 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, OKUR or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OnKure Therapeutics N/A N/A -$59.52M -$4.33 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is OKUR or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets OnKure Therapeutics N/A -61.02% -55.99% Candel Therapeutics N/A -60.42% -41.33%

Does the media favor OKUR or CADL?

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 2 articles in the media. OnKure Therapeutics' average media sentiment score of 0.94 beat Candel Therapeutics' score of 0.26 indicating that OnKure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

OnKure Therapeutics (OKUR) Competitors

$4.20 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$4.21 +0.01 (+0.24%)

As of 06/12/2026 04:10 PM Eastern

Compare

OKUR vs. CLYM, CRMD, DSGN, TLRY, and CADL

Should you buy OnKure Therapeutics stock or one of its competitors? MarketBeat compares OnKure Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OnKure Therapeutics include Climb Bio (CLYM), CorMedix (CRMD), Design Therapeutics (DSGN), Tilray Brands (TLRY), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does OnKure Therapeutics compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Climb Bio presently has a consensus target price of $21.73, indicating a potential upside of 89.92%. OnKure Therapeutics has a consensus target price of $27.00, indicating a potential upside of 542.86%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Climb Bio has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Climb Bio's return on equity of -31.45% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Climb Bio is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 17.9% of OnKure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Climb Bio had 9 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Climb Bio and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Climb Bio's score of 0.43 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Climb Bio and OnKure Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does OnKure Therapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

CorMedix has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$400.05M	1.71	$163.05M	$2.13	4.10
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

CorMedix has a net margin of 45.25% compared to OnKure Therapeutics' net margin of 0.00%. CorMedix's return on equity of 45.57% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	45.25%	45.57%	24.76%
OnKure Therapeutics	N/A	-61.02%	-55.99%

In the previous week, CorMedix had 2 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for CorMedix and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat CorMedix's score of 0.57 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CorMedix presently has a consensus price target of $15.00, suggesting a potential upside of 71.62%. OnKure Therapeutics has a consensus price target of $27.00, suggesting a potential upside of 542.86%. Given OnKure Therapeutics' higher probable upside, analysts plainly believe OnKure Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CorMedix has a beta of 1.46, suggesting that its stock price is 46% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

34.2% of CorMedix shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CorMedix beats OnKure Therapeutics on 11 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk.

Design Therapeutics' return on equity of -33.07% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
OnKure Therapeutics	N/A	-61.02%	-55.99%

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Design Therapeutics' average media sentiment score of 0.94 equaled OnKure Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Design Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Design Therapeutics presently has a consensus target price of $16.50, indicating a potential upside of 50.41%. OnKure Therapeutics has a consensus target price of $27.00, indicating a potential upside of 542.86%. Given OnKure Therapeutics' higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Summary

Design Therapeutics beats OnKure Therapeutics on 7 of the 12 factors compared between the two stocks.

How does OnKure Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

9.4% of Tilray Brands shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 0.8% of Tilray Brands shares are held by insiders. Comparatively, 17.9% of OnKure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tilray Brands has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

In the previous week, Tilray Brands had 20 more articles in the media than OnKure Therapeutics. MarketBeat recorded 22 mentions for Tilray Brands and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.94 beat Tilray Brands' score of 0.51 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	3 Very Positive mention(s)	7 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OnKure Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
OnKure Therapeutics	N/A	-61.02%	-55.99%

Tilray Brands currently has a consensus price target of $11.50, indicating a potential upside of 130.92%. OnKure Therapeutics has a consensus price target of $27.00, indicating a potential upside of 542.86%. Given OnKure Therapeutics' higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

OnKure Therapeutics has lower revenue, but higher earnings than Tilray Brands. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A

Summary

Tilray Brands beats OnKure Therapeutics on 8 of the 15 factors compared between the two stocks.

How does OnKure Therapeutics compare to Candel Therapeutics?

OnKure Therapeutics (NASDAQ:OKUR) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

OnKure Therapeutics currently has a consensus price target of $27.00, suggesting a potential upside of 542.86%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 110.28%. Given OnKure Therapeutics' higher possible upside, analysts clearly believe OnKure Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OnKure Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics is trading at a lower price-to-earnings ratio than OnKure Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OnKure Therapeutics	N/A	N/A	-$59.52M	-$4.33	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

OnKure Therapeutics has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, indicating that its share price is 149% less volatile than the broader market.

In the previous week, OnKure Therapeutics and OnKure Therapeutics both had 2 articles in the media. OnKure Therapeutics' average media sentiment score of 0.94 beat Candel Therapeutics' score of 0.26 indicating that OnKure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Candel Therapeutics' return on equity of -60.42% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OnKure Therapeutics	N/A	-61.02%	-55.99%
Candel Therapeutics	N/A	-60.42%	-41.33%

Summary

OnKure Therapeutics and Candel Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get OnKure Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OKUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OKUR vs. The Competition

Export

Metric	OnKure Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$169.68M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.97	20.00	24.00	24.42
Price / Sales	N/A	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	1.02	8.32	10.55	6.82
Net Income	-$59.52M	$23.94M	$3.57B	$337.56M
7 Day Performance	-4.55%	1.84%	0.59%	1.16%
1 Month Performance	32.91%	-0.04%	1.55%	3.16%
1 Year Performance	58.49%	44.82%	25.41%	30.60%

OnKure Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OKUR OnKure Therapeutics	2.7652 of 5 stars	$4.20 flat	$27.00 +542.9%	+58.5%	$169.68M	N/A	N/A	N/A
CLYM Climb Bio	3.7545 of 5 stars	$11.20 -5.1%	$20.30 +81.3%	+807.9%	$675.70M	N/A	N/A	9	Analyst Forecast Gap Down
CRMD CorMedix	3.441 of 5 stars	$8.17 -3.3%	$15.00 +83.6%	-40.0%	$662.92M	$311.71M	3.84	30	Gap Up
DSGN Design Therapeutics	2.8039 of 5 stars	$10.17 -2.6%	$16.50 +62.2%	+185.7%	$652.05M	N/A	N/A	40	Positive News
TLRY Tilray Brands	3.5848 of 5 stars	$5.38 -2.0%	$11.50 +113.8%	+23.3%	$639.85M	$821.31M	N/A	2,842	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OKUR) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OnKure Therapeutics (OKUR) Competitors

OKUR vs. CLYM, CRMD, DSGN, TLRY, and CADL

How does OnKure Therapeutics compare to Climb Bio?

Summary

How does OnKure Therapeutics compare to CorMedix?

Summary

How does OnKure Therapeutics compare to Design Therapeutics?

Summary

How does OnKure Therapeutics compare to Tilray Brands?

Summary

How does OnKure Therapeutics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OnKure Therapeutics (OKUR) Competitors

OKUR vs. CLYM, CRMD, DSGN, TLRY, and CADL

How does OnKure Therapeutics compare to Climb Bio?

Do analysts rate CLYM or OKUR?

Which has more volatility & risk, CLYM or OKUR?

Is CLYM or OKUR more profitable?

Which has higher earnings and valuation, CLYM or OKUR?

Do insiders & institutionals have more ownership in CLYM or OKUR?

Does the media favor CLYM or OKUR?

Summary

How does OnKure Therapeutics compare to CorMedix?

Which has better valuation and earnings, CRMD or OKUR?

Is CRMD or OKUR more profitable?

Does the media favor CRMD or OKUR?

Do analysts rate CRMD or OKUR?

Which has more volatility and risk, CRMD or OKUR?

Do insiders and institutionals have more ownership in CRMD or OKUR?

Summary

How does OnKure Therapeutics compare to Design Therapeutics?

Is DSGN or OKUR more profitable?

Does the media prefer DSGN or OKUR?

Which has preferable earnings and valuation, DSGN or OKUR?

Do institutionals & insiders believe in DSGN or OKUR?

Do analysts recommend DSGN or OKUR?

Which has more volatility and risk, DSGN or OKUR?

Summary

How does OnKure Therapeutics compare to Tilray Brands?

Do institutionals & insiders believe in TLRY or OKUR?

Which has more risk & volatility, TLRY or OKUR?

Does the media prefer TLRY or OKUR?

Is TLRY or OKUR more profitable?

Do analysts rate TLRY or OKUR?

Which has stronger valuation & earnings, TLRY or OKUR?

Summary

How does OnKure Therapeutics compare to Candel Therapeutics?

Do analysts rate OKUR or CADL?

Which has better valuation and earnings, OKUR or CADL?

Which has more risk and volatility, OKUR or CADL?

Does the media favor OKUR or CADL?

Do insiders & institutionals hold more shares of OKUR or CADL?

Is OKUR or CADL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKUR vs. The Competition

OnKure Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools